H.R. 8857 · 119th Congress · Health

Next GEN Act of 2026

In committee201 words Introduced May 15, 2026 · Latest action May 15, 2026

How far it has goneStage 2 of 6
  1. IntroducedMay 15, 2026 Done
  2. CommitteeReferred to 2 committees Current stage
  3. House floorNot yet Not reached yet
  4. Senate floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

Full text

No CRS summary yet · 201 words

H.R. 8857 · Introduced in House · May 15, 2026

SECTION 1. SHORT TITLE.

This Act may be cited as the Next Generation Medicines Act of 2026 or the Next GEN Act of 2026 .

SEC. 2. ADJUSTING RULES FOR ENGINEERED CYCLIC PEPTIDES UNDER DRUG PRICE NEGOTIATION PROGRAM.

(a) In general. Section 1192(e) of the Social Security Act ( 42 U.S.C. 1320f–1(e) ) is amended— (1) in paragraph (1)(A)(ii), by inserting (or, in the case of an engineered cyclic peptide (as defined in paragraph (5)), 11 years) after 7 years ; and (2) by adding at the end the following new paragraph: (5) Engineered cyclic peptide defined In this subsection, the term engineered cyclic peptide means a polymer that— (A) is composed principally of amino acids; (B) contains not less than 1 cyclic structure produced through head-to-tail cyclization, head-to-side-chain cyclization, side-chain-to-tail cyclization, or side-chain-to-side-chain cyclization; (C) contains not more than 40 amino acids; (D) was identified for development using a genetically encoded library screening method; (E) is not naturally derived; and (F) is orally administered, inhaled, or otherwise self-administered. .

(b) Effective date. The amendments made by this section shall apply with respect to lists published under section 1192(a) of the Social Security Act ( 42 U.S.C. 1320f–1(a) ) on or after the date of the enactment of this section.

Shown here because the text is under 500 words. Open on Congress.gov

Who lobbies on it

1 organization · 2 filings · Q2 2026–Q3 2026

See which of this bill’s sponsors and cosponsors got money from Merck & Co., Inc’s PAC → Pro

One square per quarter since introduction, oldest left. Filled = named it that quarter.

  1. Merck & Co., Inc 2 of 2 quarters
    “Issues related to Medicare Part D and Part B Pricing Reform; Issues related to H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act; Issues related to H.R. 8857 - Next GEN Act of 2026; Issues related to H.R. 10628/S.5571 - Biosimilars Access and Affordability Act.”

    $8.8M lobbying spend in 2026 to date, all issuesQ3 2026 filing

Organizations that named H.R. 8857 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. May 15, 2026Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  2. May 15, 2026Introduced in House